FDA requires NAION vision-loss warning on all GLP-1 receptor agonist labels

Tento záznam sa zobrazuje v angličtine, kým nebude aktualizovaný jeho preklad.

The FDA is requiring makers of all GLP-1 receptor agonist medicines to add information about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that causes sudden, painless vision loss in one eye and can be permanent, to the Warnings and Precautions section of their labels. In an FDA analysis of 126 randomized trials with 134,253 patients, NAION occurred at 6.4 cases per 100,000 person-years with GLP-1 drugs versus 3.8 with a placebo or other glucose-lowering medicine. In an FDA cohort study of adults with type 2 diabetes, risk was higher than with DPP-4 inhibitors (hazard ratio 1.43) but not significantly different from SGLT-2 inhibitors (hazard ratio 1.19).

Zdroj

  1. 01FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition(otvorí zdroj na novej karte) U.S. Food and Drug Administration

Dotknuté peptidy

  1. SchválenéSemaglutideAgonista receptora GLP-131
  2. SchválenéTirzepatideDuálny agonista receptorov GIP a GLP-139
  3. SchválenéLiraglutideAgonista receptora GLP-131
  4. SchválenéDulaglutideAgonista receptora GLP-1 (fúzny proteín s Fc)31
  5. SchválenéExenatideAgonista receptora GLP-139